GLP-1 medications linked to lower breast cancer incidence - Penn study

Breast cancer and obesity are closely connected. Excess adipose tissue raises oestrogen levels, increases chronic inflammation, and disrupts the hormonal environment that governs breast cell behaviour. That same biological territory is exactly where GLP-1 medications like Ozempic and Wegovy intervene. A new study from Penn Medicine, published in JCO Oncology Practice and presented at the 2026 ASCO Annual Meeting, found that women who used GLP-1 medications had 30.5% lower odds of developing breast cancer compared to matched non-users - across a dataset of 111,646 women aged 45-80.

TL;DR

Penn Medicine's study of 111,646 women found GLP-1 users had 30-35% lower odds of breast cancer, making it the largest US health system study on this question to date. The research is observational and does not confirm the drugs prevent breast cancer, but adds meaningfully to a growing body of evidence that has prompted plans for a multi-site clinical trial in high-risk women.

What the Penn study found

Led by Dr Elizabeth McDonald, Professor of Radiology at the University of Pennsylvania Perelman School of Medicine, the study analysed data from 111,646 women aged 45-80 with a BMI of 25 or above, covering the period January 2022 to June 2025. Of these, 15,264 women (13.7%) were GLP-1 users and 96,382 (86.3%) were not.

The matched cohort analysis - which controls for age, weight, comorbidities, and other confounding factors - found 30.5% lower odds of breast cancer in GLP-1 users. The full cohort analysis (less conservative) found a 35.1% reduction. The study was presented as Abstract 10506 at the 2026 ASCO Annual Meeting.

Dr McDonald was careful about the study's limitations: "While our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, it does add to the growing body of evidence suggesting that it is worth investigating these weight-loss drugs as potential cancer prevention tools."

A multi-site clinical trial is now in development, with a planned focus on high-risk women including breast cancer survivors. That trial will be the first step toward understanding whether the association is causal.

Why obesity drives breast cancer risk

Understanding why GLP-1 medications might reduce breast cancer risk requires understanding the biological links between obesity and breast cancer. They are multiple and well-established:

Oestrogen production in adipose tissue

After menopause, the ovaries stop producing most oestrogen. Adipose tissue becomes the primary source, converting androgens to oestrogen through an enzyme called aromatase. More fat tissue means more aromatase activity, higher circulating oestrogen, and a more stimulating hormonal environment for oestrogen-receptor-positive breast cancer - which accounts for roughly 70-80% of breast cancers. GLP-1 medications reduce adipose tissue substantially, and with it, the aromatase-driven oestrogen excess.

Insulin and IGF-1 signalling

Chronically elevated insulin and IGF-1 - common in obesity and metabolic syndrome - act as growth signals for breast cells. Both hormones bind receptors on breast tissue and promote cell proliferation. GLP-1 medications lower fasting insulin and improve insulin sensitivity, reducing this proliferative drive.

Chronic inflammation

Adipose tissue, particularly visceral fat, produces pro-inflammatory cytokines including TNF-alpha, IL-6, and leptin. These create a chronic low-grade inflammatory state that promotes DNA damage, impairs immune surveillance, and creates a tumour-friendly microenvironment. GLP-1 medications reduce adipose-driven inflammation significantly as body weight falls.

Adipokine imbalance

Leptin (elevated in obesity) promotes breast cell proliferation. Adiponectin (reduced in obesity) has anti-proliferative and anti-inflammatory effects. GLP-1-mediated weight loss shifts this balance - lowering leptin and raising adiponectin - toward a less pro-tumour hormonal environment.

Is the benefit from weight loss or from the drug itself?

This is the key mechanistic question the Penn study cannot answer. Both pathways are plausible. Weight loss of 10-15% on semaglutide would reduce adipose-driven oestrogen, insulin, and inflammation through purely metabolic mechanisms. But GLP-1 receptors are also expressed in breast tissue, and early preclinical research suggests direct GLP-1 receptor activation may inhibit breast cell proliferation through pathways independent of weight loss.

The clinical trial in development will be designed to separate these mechanisms. Until then, the evidence cannot distinguish between a weight-loss effect and a drug-specific anti-tumour effect.

Context: GLP-1 medications for women already diagnosed with breast cancer

The Penn study is about prevention - the risk of developing breast cancer in the first place. A separate question is whether GLP-1 medications are safe and beneficial for women who have already been diagnosed and treated for breast cancer. A 2025 narrative review published in the International Journal of Molecular Sciences analysed the available clinical evidence and found:

• GLP-1 medications showed no increased breast cancer recurrence risk in the studies reviewed
• All-cause mortality was significantly lower in GLP-1 users among cancer survivors (HR 0.36 in one study)
• Weight loss effects were meaningfully smaller in breast cancer patients on endocrine therapy (aromatase inhibitors, tamoxifen) compared to the general population - likely because hormonal therapy partially counteracts the metabolic benefits
• Cardiovascular benefits were consistent: lower all-cause mortality, reduced heart failure risk, and lower stroke risk

The reduced weight loss efficacy in patients on endocrine therapy is clinically important. Women taking aromatase inhibitors alongside a GLP-1 medication should have realistic expectations about weight loss outcomes and discuss these specifically with their oncologist.

What does this mean for women currently on a GLP-1 medication

If you take a GLP-1 medication for weight management or type 2 diabetes, the Penn study suggests you may be receiving a potential breast cancer risk reduction as a secondary benefit - particularly if you have a BMI over 25 and are in the 45-80 age range most studied. This does not change screening recommendations:

• Annual mammography at whatever age your guideline or doctor recommends is not replaced by GLP-1 therapy
• If you have a personal or family history of breast cancer, higher-risk screening protocols still apply regardless of GLP-1 use
• The observational nature of this data means it cannot establish that GLP-1 medications prevent breast cancer - the planned clinical trial is essential before any clinical recommendations change

Supporting hormonal health on GLP-1 medications

Several nutrients play active roles in the hormonal and inflammatory pathways linking obesity and breast cancer. Vitamin D has well-documented effects on cell proliferation and immune surveillance in breast tissue, and deficiency is associated with higher breast cancer risk in multiple cohort studies. Omega-3 fatty acids reduce the inflammatory cytokine environment that promotes tumour progression. Zinc supports immune function and DNA repair mechanisms. All three are among the nutrients most commonly depleted when food intake drops substantially on GLP-1 therapy.

GLP-1 Shield is formulated to address the specific nutrient gaps that GLP-1 medications create, including the nutrients that support hormonal balance and immune function while your body adapts to lower food intake.

Frequently asked questions

Does Ozempic or Wegovy reduce breast cancer risk?

The Penn Medicine study found 30-35% lower breast cancer odds in GLP-1 users, but this is observational data and cannot confirm causation. A clinical trial is in development to test this more rigorously. GLP-1 medications are not approved or prescribed for breast cancer prevention.

Why might GLP-1 medications reduce breast cancer risk?

Several mechanisms are plausible: reduced adipose-driven oestrogen production, lower insulin and IGF-1 signalling (both growth signals for breast cells), reduced chronic inflammation from adipose tissue, and potentially direct GLP-1 receptor effects in breast tissue. The Penn study cannot distinguish which mechanism is responsible.

Are GLP-1 medications safe for breast cancer survivors?

A 2025 review of available clinical evidence found no increased recurrence risk in breast cancer patients using GLP-1 medications, and significantly lower all-cause mortality in some studies. However, weight loss efficacy is reduced in patients on endocrine therapy (aromatase inhibitors, tamoxifen). Any use by breast cancer survivors should be discussed with an oncologist.

Does tirzepatide also reduce breast cancer risk?

The Penn study did not report drug-by-drug breakdowns for breast cancer specifically. The ASCO colorectal cancer data showed no significant tirzepatide effect on colorectal cancer risk - suggesting the mechanism may be specifically GLP-1-receptor-mediated rather than a class effect. Whether this extends to breast cancer is not yet known.